Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma / 临床肝胆病杂志

ABSTRACT

In recent years, immune checkpoint inhibitor (ICI) in the treatment of unresectable liver cancer has attracted great attention in China and foreign countries and great progress has been achieved, but ICI monotherapy cannot bring benefits to most patients with liver cancer. Therefore, it is a new trend to explore the combination of ICI with other treatment methods. This article summarizes the advances in ICI combination therapy for unresectable liver cancer in China and foreign countries, including ICI combined with molecular targeted therapy, PD-1/PD-L1 inhibitor combined with CTLA-4 inhibitor, and ICI combined with local therapy. The results show that for patients with unresectable liver cancer, ICI combined with other treatment methods has a significantly better effect than ICI monotherapy; however, further studies are needed to explore which treatment method combined with ICI can bring the greatest benefits to patients.